Choose Broker

Step 1
Choose a broker


Please enter your User ID and Password to place trade

Share or CFD

Step 2
Select the investment product you wish to purchase

OR

Share

Purchasing shares in a company buys you part ownership of that company. You're given the right to vote on who manages the company and receive a portion of company profits through the distribution of dividends.

Example: If a share price quote is $25, then that means one share is valued at $25.

Note: Shares are also referred to as stocks, equities and securities.

CFD

Is an abbreviation for "Contract for Difference". A CFD is a 'derivative' that is derived from the underlying value of the share price. A CFD’s allow you to go long (buy the CFD) or go short (sell the CFD).

CFD's give you leverage.

Example: Buying a CFD in XYZ provides you with an opportunity to purchase the shares at a variable rates such as 10 to 1 ratio instead of the full upfront share value cost i.e. paying $1,000 instead of $10,000.

Because CFDs are traded on margin, you must maintain the minimum margin level at all times.

Note: CFD’s are not recommended for novice traders.

Order Type

Step 3
Select your type of market order


Market Order

This is a type of order that instructs to buy or sell immediately at the best price available.

Limit Order

An order placed to buy or sell a set number of shares at a specified price or better.

Stop Order

This is an order that is executable once a set price has been reached. Once the order surpasses a particular point the order becomes a market order.

Stop Limit Order

An order placed that will be executed at a specific price or better after a given stop price has been reached. Therefore it combines the feature of a stop order with those of a limit order.

Order Period

Step 4
Select the time period that you want your trade to be live/active for.


G.T.C

Stands for good till cancelled. This means once the order is placed, the order will remain in place until someone cancels the order.

Day order

An order that if not executed, will stand until the end of the trading day.

One week

An order that will stand for a full week from the time it is placed, and then be automatically cancelled at the end of this period if it has not been executed.

One month

An order that if not executed, will stand for a full month.

End of week

An order that if not executed, will stand to the end of the trading week.

End of month

An order that if not executed, will stand to the end of the trading month.

End of year

An order that if not executed, will stand to the end of the year.

Quantity

Step 5
Select the value or quantity of how many shares you want to buy

Shares
@
$

Brokerage Fee: Please select broker first to calculate brokerage*.

Nominal Value:
$71.50 AUD

Risk Management

Step 6
Select what alarms (automatic exits) you want to protect both your investments and your profits.

Take Profit
$
OR
%
Stop Loss
$
OR
%
Trailing Stop Loss
%

Take Profit

Take-profit orders are used to lock in profits in the event the rate moves in a favorable direction. For example....

Stop Loss

Take-profit orders are used to lock in profits in the event the rate moves in a favorable direction. For example....

Trailing Stop Loss

Take-profit orders are used to lock in profits in the event the rate moves in a favorable direction. For example....

Confirm

Confirm
Please confirm your order

Buy -
Order Type -
Price -
Order Period -
Brokerage 8.00 AUD
Nominal Value -
Take Profit -
Stop Loss -
Trailing Stop Loss -
Trade Date -
There was a problem with your trade ticket. Please try again.
There was a problem submitting your trade ticket. Please try again in a minute.

Order Placed Successfully


Exit Orderpad        Place another trade
Current Price{{movement}} {{quote.Last.toFixed(3) == 0.000 ? quote['CF CLOSE'].toFixed(3) : quote.Last.toFixed(3)}} (20 minute delay)
Today's Change ${{quote['Net Change'].toFixed(3)}} ({{quote['% Change']}}%) Market is currently: {{quote['Price Qualifier Code'] == "OPN" ? "OPEN" : "CLOSED"}}
Open {{quote['Opening Price'].toFixed(3)}} Prev Close {{quote['Historic Close'].toFixed(3)}}
Today's High {{quote["Today's High"].toFixed(3)}} Today's Low {{quote["Today's Low"].toFixed(3)}}
Broker Consensus

No Data Available

  • Sell
  • Reduce
  • Hold
  • Buy
  • Strong Buy

Compumedics Limited (CMP)
is a publicly listed company on the Australian Securities Exchange (ASX).


{{businessSummary}}

1 Day
Chart Type
Themes
Select Tool
Fill:
Line:
Axis Label:
  • Open:
  • High:
  • Close:
  • Low:
  • Volume:
  • Date:

News

No News Available

{{item.Body}}



General Overview

About Compumedics

Compumedics Limited (ASX: CMP) is a medical device company involved in the development, manufacture and commercialisation of diagnostics technology for the sleep, brain and ultrasonic blood-flow monitoring applications.

The Company owns US based Neuroscan and Germany-based DWL Elektronishe GmbH. In conjunction with these two subsidiaries, Compumedics has a broad international reach, including Americas; Australia and Asia Pacific; and Europe and the Middle East.

Executive Chairman, Dr David Burton, founded Compumedics in 1987. In the same year the Company successfully designed and installed the first Australian, fully computerised Sleep Clinic at Epworth Hospital in Melbourne. Following this early success, Compumedics focused on the development of products that sold into the growing international sleep clinic and home monitoring markets. Compumedics listed on the Australian Securities Exchange in 2000.

Over the years, Compumedics has received numerous awards and accolades including Australia’s exporter of the year and has been recognised as a Top 100 Innovator by both German and Australian Governments. 

History

Compumedics was established in Melbourne in 1987, when Dr. David Burton, the Executive Chairman, was approached by Dr. Murray Johns of the Epworth Medical Clinic in Melbourne to design and install the first Australian, fully computerized Sleep Clinic.

Following the success of the Epworth Sleep Clinic installation in 1989, Compumedics focused on the development of products that sold into the growing Sleep Clinic market and the home monitoring market. This led to the release in 1991 of Compumedics’ S-Series laboratory sleep system and later the P-Series portable systems

Compumedics achieved technology endorsement, when in 1995, NASA chose its P-Series for two separate contracts, the first involving Space Shuttle mission preparation, and the second the international space station mission preparation. The P-Series was further endorsed when the Company won the right, against considerable international competition, to supply diagnostic equipment to the largest sleep study in the world, the USA-funded Sleep Heart Health Study (SHHS).

Compumedics obtained its first FDA clearance in 1997 and in 1999 Compumedics established an office in Minneapolis, Minnesota USA.

Compumedics listed on the Australian stock exchange in Dec 2000.

In April 2002, Compumedics purchased Neuroscan, the world’s premier developer of EEG and Evoked Potential systems for neurological research. This purchase firmly secured Compumedics position as a leader in this rapidly growing field of medicine.

In 2004 Compumedics acquired DWL, a German based pioneer in the field of transcranial doppler blood flow analysis.

With these acquisitions consolidated the company experienced a period of strong growth leading up to the global financial crisis of 2008 when world markets and spending on healthcare capital markets collapsed. Following the GFC, Compumedics – then a purely Australian based manufacturer – was confronted with the challenge of a rapidly rising Australian dollar.

Given these very difficult conditions Compumedics board and management made the decision to completely overhaul the business in order to not only survive but thrive in the new environment. A plan was developed for the company to be able to grow revenue, earnings and shareholder wealth despite the Aussie currency trading at parity to the US dollar. It is important to note that despite the difficult operating conditions that persisted during these years, and many of the company’s competitors failing or being acquired at bargain prices, Compumedics never lost its market leading positions and retained its focus on R&D and innovation.

Management, the board and employees spent the next few years implementing the new strategy and in 2013/14 Compumedics successfully returned to operating profitability.

In 2015 with the effects of off-shoring manufacturing and assembly, revitalising the product range through extensive R&D to open up new markets and the Aussie dollar returning to a more normal level Compumedics was able to achieve $2m Net Profit After Tax, more than double the prior year, with the company now in a position to continue to drive earnings growth and further shareholder wealth in the years to come. As a result of this turnaround shareholders have been rewarded with the stock price surpassing decade highs in 2015.

With the full effects of the above strategy yet to flow through to earnings, the company’s push into the exciting and potentially very lucrative e-Health space, strong earnings growth forecast for FY16 and growing investor interest the future looks very bright for Compumedics. 

Research and Development

Compumedics believes that it has remained at the forefront of the physiological data recording/diagnostics market by maintaining an active research and development program.

Compumedics has a highly skilled research team and has developed significant intellectual property. These resources, together with the Medical Advisory Board allow the company to continue to develop the best diagnostic products for the medical market.

To ensure that there is a regular pipeline of new and innovative products, the Company has established a dedicated innovation group. The role of the Innovation Group is to work closely with the Medical Advisory Board and the medical and research communities in identifying future product trends, paradigm shifts in technology and health decrease trends.

Distribution and Marketing

Compumedics provides its products via an established international network of distributors and direct sales offices.

Compumedics has its global corporate headquarters in Melbourne, Australia, and field offices in the USA, Singapore, Hong Kong and Germany.

Compumedics works closely with each of its distributors in identifying customer needs and providing optimal service and support to both the distributors and the ultimate user of the product. It is the distributor's responsibility to sell directly to end-users in their particular territories.

The Company's global sales and marketing activities are coordinated from the Corporate Headquarters in Melbourne, Australia.

Customers

Compumedics is the supplier of choice for an increasing number of leading researchers, universities and hospitals around the world.  Their equipment is installed in a number of highly acclaimed medical centers globally :

  • The Mayo Clinic, Rochester, Minnesota (USA)
  • Shands Medical Center, University of Florida, Gainesville, Florida (USA)
  • University of California, San Diego California (USA)
  • Walter Reed Army Hospital, Washington, DC (USA)
  • The Cleveland Clinic, Cleveland, Ohio (USA)
  • Royal Prince Alfred Hospital (NSW, Australia)
  • Royal Children's Hospital (Vic, Australia)
  • Austin Health (Vic, Australia)
  • Hennepin County Medical Center, Minneapolis, Minnesota (USA)
  • Royal Edinburgh Infirmary (UK)
  • University Hospitals, Cleveland, Ohio (USA)
  • NASA (USA)

Products

Sleep Diagnostics

Laboratory Based
High Definition Solution

For those with a need for clearer, more precise data for sleep studies and a more advanced capabilities in data analysis and data management, the high-definition package from Compumedics delivers. With the increasing interest in low frequency and high frequency EEG analysis to discriminate certain sleep disorders and the desire to have more physiologic responses for SpO2, nasal pressure and other parameters, digital amplifiers and signal processing should be uncompromising in there design.

The high-definition solution includes the latest digital amplifier technology and advanced applications software with available tools such as CAPS analysis and ECG analysis. 

High Value Solution

When looking for the most cost-effective polysomnography solution for the laboratory setting, the high-value package from Compumedics provides a complete solution. With a choice of proven amplifiers, application software that is easy to use and quick to master, and a digital video solution that provides clear imaging and sound recording, your needs are met with high-value.

Ambulatory

Full PSG Ambulatory

When looking for an ambulatory sleep solution with full PSG capabilities, the Somte PSG system is the solution you seek.

  • The simple patient-worn unit allows rapid setup and use of the system anywhere
  • Fully self-contained – No PC or laptop is required to setup and acquire data
  • System can be programmed to automatically start and stop recording at pre-set times
  • Integrated LCD screen to check the quality of signals before or during recording
  • Unique signal status display for instant signal integrity and impedance checks. Signal integrity can be displayed during data review for quality assurance.
  • Integrated Compact Flash storage card for up to 24 hours data collection
  • Uses analogue differential amplifiers for the simplest and most robust recording of physiological signals, even in less than ideal situations
Wireless Ambulatory PSG

Expand your options for PSG studies with the Siesta wireless PSG system. It is small, lightweight and provides wireless transmission for flexibility in PSG recording.

Home Sleep Testing

In many areas of the world, the home is the setting where a large percentage of diagnostic sleep studies are performed. Compumedics has been involved with the home sleep testing (HST) market since it released its first portable systems in 1995. Their products provide basic Type III portable testing, when respiratory event detection is the primary need and Type II portable testing, when advanced sleep testing in the home is required, including full sleep staging. Systems are easy to apply, reliable to operate and provide excellent signal quality.

Operating on the same applications platform that their lab systems use, the studies can be quickly scored and reports generated. The studies can be integrated into the neXus Laboratory Management System

Full PSG Home Sleep Testing

When looking for a solution for full PSG home sleep testing, the Somte PSG system is the ideal solution you seek.

  • Maximum patient freedom and comfort
  • The simple patient-worn unit allows rapid setup and use of the system anywhere
  • Fully self-contained – No PC or laptop is required to setup and acquire data
  • System can be programmed to automatically start and stop recording at pre-set times
  • Integrated LCD screen to check the quality of signals before or during recording
  • Unique signal status display for instant signal integrity and impedance checks. Signal integrity can be displayed during data review for quality assurance.
  • Integrated Compact Flash storage card for up to 24 hours data collection
  • Uses analogue differential amplifiers for the simplest and most robust recording of physiological signals, even in less than ideal situations.
Limited Channel Home Sleep Testing

See more and do more with Somte for Home Sleep Testing (HST)

For out-of-center sleep testing for Obstructie Sleep apnea, the Somte system reliably captures the basic data you need, and when you want a better insight into the patient, the Somte has more to offer. Compumedics’ years of experience in HST diagnostic testing is well reflected in the design of the Somte.

Insight into sleep apnea with home sleep testing

To get the most of home sleep testing you need a system that

  • captures high-quality and reliable signals
  • is easy to use
  • provides quick analysis and
  • provides an easy to read report

The Somte system provides just this type of experience for a better insight into sleep apnea in the home.

Cardio-respitory Testing

Congestive Heart Failure affects million of people around the world. It has been estimated that nearly half of these individuals exhibit sleep disordered breathing patterns.

Introducing Somté, a new investigative tool for "holter-style" recording of a wide range of physiological data. Somté software provides comprehensive analyses to assist in understanding the nature and severity of the interrelated respiratory and cardiac diseases.

Somté

The Somté assembles a technologically advanced pager-size recorder with powerful and comprehensive analysis software for the clinician. This new investigative tool is designed for ‘holter-style’ recording of both respiratory and cardiac data.
Congestive Heart Failure affects million of people around the world. It has been estimated that nearly half of these individuals exhibit sleep disordered breathing patterns.

Now, Compumedics introduces Somté, a new investigative tool for “holter-style” recoding of a wide range of physiological data. Somté software provides comprehensive analyses to assist in understanding the nature and severity of the interrelated respiratory and cardiac diseases.


Neurology Diagnostics

Clinical Routine EEG
High Definition

For clinical diagnostic EEG studies and pre-op and post-op assessments the Grael 4K-EEG system blends the latest digital amplifier technology with powerful software packaged in a custom designed cart that is mobile, convenient and flexible.

The Grael 4K-EEG System integrates with their advanced neXus Lab Management System, to deliver a fully-featured solution for managing and maintaining patient and study data with an optional interface to the facility EMR (via HL7) and secure remote access. Compumedics brings the next level of innovation to Routine Clinical EEG with the Grael EEG System. Enjoy the advantages of High-Definition EEG in a total package that was designed for efficiency and productivity.

High Value Solution

When looking for a cost-effective EEG solution for the laboratory setting, consider the high-value package from Compumedics.  With reliable amplifiers, application software that is easy to use and quick to master, and a digital video solution that provides clear imaging and sound recording, your needs are met with high-value.

Running the system is a breeze with Profusion EEG software, quickly stepping the operator through acquisition to report generation, with features not often found in clinical EEG systems.

All in all, the reliability and performance of this package meet the needs of today’s value focused operation.

Ambulatory EEG Solution
Wireless Ambulatory EEG

The Siesta product line was developed to provide up to 32 channels of recording and with the latest version, the Siesta802a coupled with their new Extended Battery Pack, users can record multiple days of EEG on a reliable platform and quickly download and review the data.

Standard Ambulatory EEG Solution

The Safiro system offers convenience, capability and confidence for all your ambulatory EEG recording needs. Compumedics superior digital technology allows for simple operation and better quality recordings.

Continuous EEG (cEEG) monitoring for ICU
Grael eEEG Cart Solution

Built on a small footprint cart system (design varies by region) the Grael HD-EEG system blends the latest digital amplifier technology with powerful recording, trending and reviewing software. The Grael HD-EEG System is network linked and supports secure remote access. Compumedics brings the next evel of innovation to cEEG with the Grael cEEG System. Enjoy the advantages of High-Definition EEG in a total package that was designed for efficiency and productivity.

Neuvo cEEG Cart Solution

The amplifier systems include wireless communication capabilities which support real-time monitoring and even support the use of synchronized digital video. These systems have been proven in several large research protocols, with documented ruggedness and superior signal quality.

Long Term Monitoring LTM
Neuvo 64-512 Channel EEG HD-LTM EEG Solution

Long term EEG monitoring (LTM) has evolved from systems that provided only 32 channels of EEG to today’s top level centers that look for 256 or more channels of cortical EEG recording at higher sampling and storage rates and for extended periods of time. Compumedics has a fully developed solution for virtually every need including ambulatory LTM, high-density LTM - up to 512 channels of EEG at 10,000Hz/channel storage rates with high-definition digital video and the most advanced toolset supporting multimodal analysis of EEG, MEG and imaging data.

Grael HD-EEG LTM Solution

If the need is to record up to 40 channels of data, The Grael HD-EEG system provides a great solution, blending the latest digital amplifier technology with powerful recording, trending and reviewing software. The Grael HD-EEG System is network linked and supports central station monitoring and secure remote access. Compumedics brings the next level of innovation to LTM EEG with the Grael HD-EEG System. Enjoy the advantages of High-Definition EEG in a total package that was designed for efficiency and productivity.

Siesta802A LTM EEG Solution

When you need to allow more freedom of movement for the patient during 32-channel LTM studies, such as pediatric evaluations, Compumedics has a unique solution. The Siesta 802a system is a small, lightweight, patient-worn EEG recorder with wireless data transmission features. Coupled with the latest application software for data acquisition, trending and reviewing, you can expect reliable data in the patient room, the day room and in between.

The amplifier system include wireless communication capabilities for real-time monitoring and even support switching between multiple cameras for synchronized digital video.

EMG Systems
Xegis Forte EMG/EP

Compumedics presents the next generation of Xegis EMG/EP solutions – Xegis Forté and Xegis G:Neo, a comprehensive suite of EMG/EP solutions ranging from 2 to 17- channel configurations. The new Xegis Forté and G:Neo range offers flexibility, customization, versatility and importantly, high performance and reliability.

Xegis G:Neo 2 Channel EMG/EP

A comprehensive suite of new generation Xegis EMG/EP solutions ranging from 5 to 17- channel configurations. The new Xegis Forté offers flexibility, customization, versatility and importantly, high performance and reliability.

Transcranial Doppler Sonography

Compumedics provides Transcranial Doppler Sonography solutions through the Compumedics DWL brand.

Transcranial Doppler sonography and its unique performance in measuring and analyzing flow velocity in blood vessels and detecting cerebral micro emboli is their core competency. Since 1992 Compumedics have, in close cooperation with scholars and research institutes throughout the world, perfected diagnostic methods, developed new applications, and created Doppler systems, which combine cutting edge performance with unmatched ease of use.

Brain Research

Compumedics Neuroscan

Compumedics high-fidelity technologies are used in some of the world’s foremost research institutions.

In the arena of Neurology Research, Compumedics Neuroscan technologies provides world-leading solutions for EEG, ERPs, Source Localisation and Functional Neuro-imaging.

Compumedics Neuroscan provides complete solutions for a wide range of Neuroscience applications. Compumedics Neuroscan is dedicated to developing the most sophisticated tools for the investigation of the central nervous system. Compumedics Neuroscan’s research and development teams work to evolve high-density EEG recordings into a true functinal neuro-imaging method.


Price History

52 Week High Change from 52 Week High % Change from 52 Week High 52 Week Low Change from 52 Week Low % Change from 52 Week Low
${{quote["Year's High"]}} ${{(quote["Historic Close"] - quote["Year's High"]) | setDecimalCheckForNa}} {{(((quote["Historic Close"] / quote["Year's High"]) - 1) * 100) | setDecimalCheckForNa}}% ${{quote["Year's Low"] | setDecimalCheckForNa}} ${{(quote["Historic Close"] - quote["Year's Low"])| setDecimalCheckForNa}} {{(((quote["Historic Close"] / quote["Year's Low"]) - 1) * 100) | setDecimalCheckForNa}}%
Date Open High Low Close Volume

Dividend Information

Dividend Yield Dividend Yield (5 Yr Avg) ISIN Stock Code (RIC) SEDOL Dividend Currency
{{ratios.Valuation.DivYield_CurTTM.Value | setDecimalCheckForNa}} {{ratios.Valuation.YLD5YAVG.Value | setDecimalCheckForNa}} {{Dividends[0].ISIN}} {{Dividends[0].RIC}} {{Dividends[0].SEDOL}} {{Dividends[0].DividendCurrency != '' ? Dividends[0].DividendCurrency : '-'}}

Year CorpActID DPTD DivAnnDate DivExDate DivPayDate DTMD DivRate DRD DRPrice DTMD DTMD Frank%
{{item.DividendExDate == '00/01/1900' ? '-' : item.DividendExDate}} {{item.CorporateActionsID}} {{item.DividendPaymentTypeDescription}} {{item.DividendAnnoucementDate == '00/01/1900' ? '-' : item.DividendAnnoucementDate}} {{item.DividendExDate == '00/01/1900' ? '-' : item.DividendExDate}} {{item.DividendPayDate == '00/01/1900' ? '-' : item.DividendPayDate}} {{item.DividendTypeMarkerDescription}} {{item.DividendRate != '0' ? item.DividendRate : '-'}} {{item.DividendReinvestmentDeadline == '00/01/1900' ? '-' : item.DividendReinvestmentDeadline}} {{item.DividendReinvestmentPrice != '0' ? item.DividendReinvestmentPrice : '-'}} {{item.DividendTaxMarkerDescription != '' ? item.DividendTaxMarkerDescription : '-'}} {{item.DividendTaxRate != '0' ? item.DividendTaxRate :'-'}} {{item.FrankingPercent != '0' ? item.FrankingPercent : '-'}}

Share Statistics

  Revenue/Share Free Cash Flow Per Share Cash Flow Per Share Book Value Per Share Book Value(tangible) Per Share Cash Per Share
Most Recent Quarter - - - {{ratios['Per share data'].QBVPS.Value | setDecimalCheckForNa}} {{ratios['Per share data'].QTANBVPS.Value | setDecimalCheckForNa}} {{ratios['Per share data'].QCSHPS.Value | setDecimalCheckForNa}}
Most Recent Fiscal Year {{ratios['Per share data'].AREVPS.Value | setDecimalCheckForNa}} - {{ratios['Per share data'].ACFSHR.Value | setDecimalCheckForNa}} {{ratios['Per share data'].ABVPS.Value | setDecimalCheckForNa}} {{ratios['Per share data'].ATANBVPS.Value | setDecimalCheckForNa}} {{ratios['Per share data'].ACSHPS.Value | setDecimalCheckForNa}}
Trailing 12 Months {{ratios['Per share data'].TTMREVPS.Value | setDecimalCheckForNa}} {{ratios['Per share data'].TTMFCFSHR.Value | setDecimalCheckForNa}} {{ratios['Per share data'].TTMCFSHR.Value | setDecimalCheckForNa}} - - -
  Dividend Per Share EPS Normalized EPS Basic Exluding Extraordinary Items EPS Including Extraordinary Items EPS Excluding Extraordinary Items EBITD Per Share
Most Recent Fiscal Year {{ratios['Per share data'].ADIVSHR.Value | setDecimalCheckForNa}} {{ratios['Per share data'].AEPSNORM.Value | setDecimalCheckForNa}} {{ratios['Per share data'].ABEPSXCLXO.Value | setDecimalCheckForNa}} {{ratios['Per share data'].AEPSINCLXO.Value | setDecimalCheckForNa}} {{ratios['Per share data'].AEPSXCLXOR.Value | setDecimalCheckForNa}} -
Trailing 12 Months {{ratios['Per share data'].TTMDIVSHR.Value | setDecimalCheckForNa}} - {{ratios['Per share data'].TTMBEPSXCL.Value | setDecimalCheckForNa}} {{ratios['Per share data'].TTMEPSINCX.Value | setDecimalCheckForNa}} {{ratios['Per share data'].TTMEPSXCLX.Value | setDecimalCheckForNa}} {{ratios['Per share data'].TTMEBITDPS.Value | setDecimalCheckForNa}}
5 Year Average {{ratios['Per share data'].ADIV5YAVG.Value | setDecimalCheckForNa}} - - - - -
Avg Vol(3 month) Avg Vol(10 day) Shares Outstanding Float % Held by Insiders % Held by Institutions Shares Short Shares Ratio Short % of Float Shares Short(prior month)
{{ratios['Price and Volume'].VOL3MAVG.Value | checkForNa}} {{ratios['Price and Volume'].VOL10DAVG.Value | checkForNa}} - - - - - - - -
Common Shareholders Shares Outstanding Shares Issued Float
{{generalInfo.CompanyGeneralInfo.CommonShareholders.Value | checkForNa}} {{sharesIssuedData.SharesOut | abbreviateNumber | checkForNa}} {{sharesIssuedData.SharesIssued | abbreviateNumber | checkForNa}} {{sharesIssuedData.Float | abbreviateNumber | checkForNa}}
Index Code Index name
{{item}} {{generalInfo.IndexMembership[item]}}
N/A N/A
Order Industry Type Code Mnemonic Reported
N/AN/AN/AN/AN/AN/A
{{detail.Order | checkForNa}} {{detail.Description | checkForNa}} {{industry | checkForNa}} {{detail.Code | checkForNa}} {{detail.Mnemonic | checkForNa}}

Valuation Ratios

  P/E excluding extraordinary items P/E Normalized P/E Basic excluding extraordinary items P/E excluding extraordinary items high P/E excluding extraordinary items low P/E including extraordinary items
Most Recent Fiscal Year {{ratios.Valuation.APEEXCLXOR.Value | setDecimalCheckForNa}} {{ratios.Valuation.APENORM.Value | setDecimalCheckForNa}} - - - -
TTM {{ratios.Valuation.PEEXCLXOR.Value | setDecimalCheckForNa}} - {{ratios.Valuation.PEBEXCLXOR.Value | setDecimalCheckForNa}} {{ratios.Valuation.TTMPEHIGH.Value | setDecimalCheckForNa}} {{ratios.Valuation.TTMPELOW.Value | setDecimalCheckForNa}} {{ratios.Valuation.PEINCLXOR.Value | setDecimalCheckForNa}}
  Price to Sales Price to Tangible Book Price to Free Cash Flow per Share Price to Cash Flow per Share Price to Book
Most Recent Fiscal Year {{ratios.Valuation.APR2REV.Value | setDecimalCheckForNa}} {{ratios.Valuation.APR2TANBK.Value | setDecimalCheckForNa}} {{ratios.Valuation.APRFCFPS.Value | setDecimalCheckForNa}} - {{ratios.Valuation.APRICE2BK.Value | setDecimalCheckForNa}}
Trailing 12 Months {{ratios.Valuation.TTMPR2REV.Value | setDecimalCheckForNa}} - {{ratios.Valuation.TTMPRFCFPS.Value | setDecimalCheckForNa}} {{ratios.Valuation.TTMPRCFPS.Value | setDecimalCheckForNa}} -
Most Recent Quarter - {{ratios.Valuation.PR2TANBK.Value | setDecimalCheckForNa}} - - {{ratios.Valuation.PRICE2BK.Value | setDecimalCheckForNa}}
Dividend Yield - 5 Year Average {{ratios.Valuation.YLD5YAVG.Value | setDecimalCheckForNa}}
Dividend Yield - indicated annual dividend divided by closing price {{ratios.Valuation.YIELD.Value | setDecimalCheckForNa}}
Current Dividend Yield - Common Stock Primary Issue, LTM {{ratios.Valuation.DivYield_CurTTM.Value | setDecimalCheckForNa}}
Net Debt, LFI {{ratios.Valuation.NetDebt_I.Value | setDecimalCheckForNa}}
Net Debt, LFY {{ratios.Valuation.NetDebt_A.Value | setDecimalCheckForNa}}

Financial Strength Ratios

  Current ratio Quick ratio LT debt/equity Total debt/total equity
Most Recent Quarter {{ratios['Financial strength'].QCURRATIO.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].QQUICKRATI.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].QLTD2EQ.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].QTOTD2EQ.Value | setDecimalCheckForNa}}
Most Recent Fiscal Year {{ratios['Financial strength'].ACURRATIO.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].AQUICKRATI.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].ALTD2EQ.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].ATOTD2EQ.Value | setDecimalCheckForNa}}
  Payout ratio Current EV/Free Cash Flow Interest coverage Total debt/total equity
Most Recent Fiscal Year {{ratios['Financial strength'].APAYRATIO.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].EV2FCF_CurA.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].AINTCOV.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].ATOTD2EQ.Value | setDecimalCheckForNa}}
Trailing 12 Months {{ratios['Financial strength'].TTMPAYRAT.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].EV2FCF_CurTTM.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].TTMINTCOV.Value | setDecimalCheckForNa}} -
Income Statement Revenue EBITD Earnings before taxes Net Income available to common Earnings before taxes Normalized Earnings per Share, Normalized, Excluding Extraordinary Items, Avg. Diluted Shares Outstanding
Most Recent Fiscal Year {{ratios['Income Statement'].AREV.Value | setDecimalCheckForNa}} {{ratios['Income Statement'].AEBITD.Value | setDecimalCheckForNa}} {{ratios['Income Statement'].AEBT.Value | setDecimalCheckForNa}} {{ratios['Income Statement'].ANIAC.Value | setDecimalCheckForNa}} {{ratios['Income Statement'].AEBTNORM.Value | setDecimalCheckForNa}} -
Trailing 12 Months {{ratios['Income Statement'].TTMREV.Value | setDecimalCheckForNa}} {{ratios['Income Statement'].TTMEBITD.Value | setDecimalCheckForNa}} {{ratios['Income Statement'].TTMEBT.Value | setDecimalCheckForNa}} {{ratios['Income Statement'].TTMNIAC.Value | setDecimalCheckForNa}} - {{ratios['Income Statement'].VDES_TTM.Value | setDecimalCheckForNa}}
  Gross Margin Net Profit Margin % Operating Margin Pre Tax Margin Free Operating Cash Flow/Revenue
1st Historical Fiscal Year {{ratios.Margins.AGROSMGN.Value | setDecimalCheckForNa}} {{ratios.Margins.ANPMGNPCT.Value | setDecimalCheckForNa}} {{ratios.Margins.AOPMGNPCT.Value | setDecimalCheckForNa}} {{ratios.Margins.APTMGNPCT.Value | setDecimalCheckForNa}} -
Trailing 12 Months {{ratios.Margins.TTMGROSMGN.Value | setDecimalCheckForNa}} {{ratios.Margins.TTMNPMGN.Value | setDecimalCheckForNa}} {{ratios.Margins.TTMOPMGN.Value | setDecimalCheckForNa}} {{ratios.Margins.TTMPTMGN.Value | setDecimalCheckForNa}} {{ratios.Margins.Focf2Rev_TTM.Value | setDecimalCheckForNa}}
5 Year Average {{ratios.Margins.GROSMGN5YR.Value | setDecimalCheckForNa}} {{ratios.Margins.MARGIN5YR.Value | setDecimalCheckForNa}} {{ratios.Margins.OPMGN5YR.Value | setDecimalCheckForNa}} {{ratios.Margins.PTMGN5YR.Value | setDecimalCheckForNa}} {{ratios.Margins.Focf2Rev_AAvg5.Value | setDecimalCheckForNa}}
Risk Ratio Current Ratio Quick Ratio Interest Coverage LT Debt/Equity Total Debt/Total equity
Most Recent Quarter {{ratios['Financial strength'].QCURRATIO.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].QQUICKRATI.Value | setDecimalCheckForNa}} - {{ratios['Financial strength'].QLTD2EQ.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].QTOTD2EQ.Value | setDecimalCheckForNa}}
Most Recent Fiscal Year {{ratios['Financial strength'].ACURRATIO.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].AQUICKRATI.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].AINTCOV.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].ALTD2EQ.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].ATOTD2EQ.Value | setDecimalCheckForNa}}
Trailing 12 Months - - {{ratios['Financial strength'].TTMINTCOV.Value | setDecimalCheckForNa}} - -

Management Effectiveness Ratios

Turnover Asset Inventory Receivables
Most Recent Fiscal Year {{ratios['Mgmt Effectiveness'].AASTTURN.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].AINVTURN.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].ARECTURN.Value | setDecimalCheckForNa}}
Trailing 12 Months {{ratios['Mgmt Effectiveness'].TTMASTTURN.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].TTMINVTURN.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].TTMRECTURN.Value | setDecimalCheckForNa}}
Return on Average Assets EBITD Equity Investment
Most Recent Fiscal Year {{ratios['Mgmt Effectiveness'].AROAPCT.Value | setDecimalCheckForNa}} - {{ratios['Mgmt Effectiveness'].AROEPCT.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].AROIPCT.Value | setDecimalCheckForNa}}
Trailing 12 Months {{ratios['Mgmt Effectiveness'].TTMROAPCT.Value | setDecimalCheckForNa}} - {{ratios['Mgmt Effectiveness'].TTMROEPCT.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].TTMROIPCT.Value | setDecimalCheckForNa}}
5 Year Average {{ratios['Mgmt Effectiveness'].AROA5YAVG.Value | setDecimalCheckForNa}} - {{ratios['Mgmt Effectiveness'].AROE5YAVG.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].AROI5YRAVG.Value | setDecimalCheckForNa}}
Employees Net Income Revenue
Most Recent Fiscal Year {{ratios['Mgmt Effectiveness'].ANIPEREMP.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].AREVPEREMP.Value | setDecimalCheckForNa}}
Trailing 12 Months {{ratios['Mgmt Effectiveness'].TTMNIPEREM.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].TTMREVPERE.Value | setDecimalCheckForNa}}

Growth Ratios

Growth Rates Revenue % EPS Dividend Revenue/Share Book Value Per Share Capital Spending Net Profit Margin
Most Recent Quarter 1 Year Ago {{ratios.Growth.REVCHNGYR.Value | setDecimalCheckForNa}} {{ratios.Growth.EPSCHNGYR.Value | setDecimalCheckForNa}} - - - - -
5 Years {{ratios.Growth.REVTRENDGR.Value | setDecimalCheckForNa}} {{ratios.Growth.EPSTRENDGR.Value | setDecimalCheckForNa}} - {{ratios.Growth.REVPS5YGR.Value | setDecimalCheckForNa}} {{ratios.Growth.BVTRENDGR.Value | setDecimalCheckForNa}} {{ratios.Growth.CSPTRENDGR.Value | setDecimalCheckForNa}} {{ratios.Growth.NPMTRENDGR.Value | setDecimalCheckForNa}}
3 Years {{ratios.Growth.REVGRPCT.Value | setDecimalCheckForNa}} {{ratios.Growth.EPSGRPCT.Value | setDecimalCheckForNa}} {{ratios.Growth.DIVGRPCT.Value | setDecimalCheckForNa}} - - - -
TTM over TTM {{ratios.Growth.EPSTRENDGR.Value | setDecimalCheckForNa}} {{ratios.Growth.TTMEPSCHG.Value | setDecimalCheckForNa}} - - - - -
CAGR Free Operating Cash Flow Earnings Before Interest, Taxes, Depreciation & Amortization Tangible Book Value Total Debt
5 Year CAGR {{ratios.Growth.FOCF_AYr5CAGR.Value | setDecimalCheckForNa}} {{ratios.Growth.Ebitda_AYr5CAGR.Value | setDecimalCheckForNa}} {{ratios.Growth.TanBV_AYr5CAGR.Value | setDecimalCheckForNa}} {{ratios.Growth.STLD_AYr5CAGR.Value | setDecimalCheckForNa}}
5 Year Interim CAGR - {{ratios.Growth.Ebitda_TTMY5CAGR.Value | setDecimalCheckForNa}} - -

Forecast Ratios

Projected Sales ProjSalesH ProjSalesL ProjSalesNumOfEst ProjSalesPS
{{forecasts.ProjSales | setDecimalCheckForNa}} {{forecasts.ProjSalesH | setDecimalCheckForNa}} {{forecasts.ProjSalesL | setDecimalCheckForNa}} {{forecasts.ProjSalesNumOfEst | setDecimalCheckForNa}} {{forecasts.ProjSalesPS | setDecimalCheckForNa}}
ProjSalesQ ProjSalesQH ProjSalesQL ProjSalesQNumOfEst Price2ProjSales
{{forecasts.ProjSalesQ | setDecimalCheckForNa}} {{forecasts.ProjSalesQH | setDecimalCheckForNa}} {{forecasts.ProjSalesQL | setDecimalCheckForNa}} {{forecasts.ProjSalesQNumOfEst | setDecimalCheckForNa}} {{forecasts.Price2ProjSales | setDecimalCheckForNa}}
ProjEPS ProjEPSHigh ProjEPSLow ProjEPSNumOfEst ProjEPSQ
{{forecasts.ProjEPS | setDecimalCheckForNa}} {{forecasts.ProjEPSH | setDecimalCheckForNa}} {{forecasts.ProjEPSL | setDecimalCheckForNa}} {{forecasts.ProjEPSNumOfEst | setDecimalCheckForNa}} {{forecasts.ProjEPSQ | setDecimalCheckForNa}}
ProjEPSQH ProjEPSQL ProjEPSQNumOfEst ProjPE ProjLTGrowthRate
{{forecasts.ProjEPSQH | setDecimalCheckForNa}} {{forecasts.ProjEPSQL | setDecimalCheckForNa}} {{forecasts.ProjEPSQNumOfEst | setDecimalCheckForNa}} {{forecasts.ProjPE | setDecimalCheckForNa}} {{forecasts.ProjLTGrowthRate | setDecimalCheckForNa}}
TargetPrice EPSActual EPSPrev EPSSurprise EPSSurprisePrc
{{forecasts.TargetPrice | setDecimalCheckForNa}} {{forecasts.EPSActual | setDecimalCheckForNa}} {{forecasts.EPSPrev | setDecimalCheckForNa}} {{forecasts.EPSSurprise | setDecimalCheckForNa}} {{forecasts.EPSSurprisePrc | setDecimalCheckForNa}}
EPSActualQ EPSPrevQ EPSSurpriseQ EPSSurpriseQPrc
{{forecasts.EPSActualQ | setDecimalCheckForNa}} {{forecasts.EPSPrevQ | setDecimalCheckForNa}} {{forecasts.EPSSurpriseQ | setDecimalCheckForNa}} {{forecasts.EPSSurpriseQPrc | setDecimalCheckForNa}}
ProjProfit ProjProfitH ProjProfitL ProjProfitNumOfEst
{{forecasts.ProjProfit | setDecimalCheckForNa}} {{forecasts.ProjProfitH | setDecimalCheckForNa}} {{forecasts.ProjProfitL | setDecimalCheckForNa}} {{forecasts.ProjProfitNumOfEst | setDecimalCheckForNa}}
ProjDPS ProjDPSH ProjDPSL ProjDPSNumOfEst
{{forecasts.ProjDPS | setDecimalCheckForNa}} {{forecasts.ProjDPSH | setDecimalCheckForNa}} {{forecasts.ProjDPSL | setDecimalCheckForNa}} {{forecasts.ProjDPSNumOfEst | setDecimalCheckForNa}}

Financial Reports

Financial Summary

Last Updated: {{generalInfo.TextInfo['Financial Summary'].LastUpdated}}

{{generalInfo.TextInfo['Financial Summary'].Value && generalInfo.TextInfo['Financial Summary'].Value != ''? generalInfo.TextInfo['Financial Summary'].Value: 'No Financial Summary Found.'}}


Accounting Notes
Fiscal Year Ends Most Recent Quarter Transfer agent Auditor Shariah Compliant

{{generalInfo.CompanyGeneralInfo.TotalSharesOut.Data | date:'dd/MM/yyyy' }}

-

- - {{generalInfo.Auditor && generalInfo.Auditor != ''? generalInfo.Auditor : '-'}}
Fiscal Period
Period End Date:
Period Length
Ratios Value
Analyst Footnotes

Last Updated: {{generalInfo.TextInfo['Analyst Footnotes'].LastUpdated}}

{{generalInfo.TextInfo['Analyst Footnotes'].Value && generalInfo.TextInfo['Analyst Footnotes'].Value != '' ? generalInfo.TextInfo['Analyst Footnotes'].Value : 'No Analyst Footnotes Found.'}}



Directors, Officers & Company Executives

Start Date End Date
{{personobject.PersonInformation.Name.Info| getDirectorFullNameIncludingPrefix}}
{{persontitlesobject.Value}}, {{persontitles.Start.Day}}-{{persontitles.Start.Month}}-{{persontitles.Start.Year}} {{persontitles.End.Day}}-{{persontitles.End.Month}}-{{persontitles.End.Year}}
No Directors, Officers & Company Executives Information Found.

Recommendation Statistics

No Recommendation Statistics

Recommendation Statistics
Recommendation Number Of Analysts
{{stats.Recommendation}} {{stats.NumberOfAnalysts}}
I/B/E/S Mean
{{verdict[meanmarker]}} {{analystvotes}} Analysts Mean recommendation from all analysts covering the company on a standardized 5-point scale.
  • Sell
  • Reduce
  • Hold
  • Buy
  • Strong Buy

Past Broker Recommendations

No Past Recommendations

Past Broker Recommendations
  Strong Buy Buy Hold Underperform Sell Total
{{snapshots.Age === 1 ? "1 Week Ago" : (snapshots.Age === 2 ? "30 Days Ago" : (snapshots.Age === 3 ? "60 Days Ago" : (snapshots.Age === 4 ? "90 Days Ago" : "")))}} {{snapshots.Statistics[0].NumberOfAnalysts}} {{snapshots.Statistics[1].NumberOfAnalysts}} {{snapshots.Statistics[2].NumberOfAnalysts}} {{snapshots.Statistics[3].NumberOfAnalysts}} {{snapshots.Statistics[4].NumberOfAnalysts}} {{snapshots.NumberOfRecommendations}}

Target Price

No Target Price

Target Price
Mean {{priceTarget.Mean}}
High {{priceTarget.High}}
Low {{priceTarget.Low}}
Median {{priceTarget.Median}}
Standard Devitation {{priceTarget.StandardDeviation}}
Number Of Estimates {{priceTarget.NumberOfEstimates}}

Videos

No Videos Found

Click here to view video

{{video.summary}}




Contact Info

Compumedics Limited

30-40 Flockhart Street
Abbotsford, VIC
Australia, 3067

Phone: +61 3 8420 7300
Fax: +61 3 8420 7399
Email: support@compumedics.com.au
Website: http://www.compumedics.com

Click here to view the interactive map
Compumedics Limited Google Map
Compumedics Limited Google Map

Share Registry

Link Market Services Limited - Click here to view share registry profile

Phone: +61 2 8280 7100
Fax: N/A
Email: info@linkmarketservices.com.au
Website: http://www.linkmarketservices.com.au/

Level 12
680 George Street
Sydney, NSW
AU Australia, 2000


Important Information

This profile was last edited on 28 Jul 2016.

All Financial Data is provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Share Prices nor any independent data provider is liable for any informational errors, omissions or other defects, incompleteness, or delays, or for any actions taken in reliance on Financial Data.

Please read our Terms & Conditions and Disclaimer Statement for further information.

Home

Search

Login

Register

Report a bug